Business Context and Reporting Period
Company: ARCA Biopharma, Inc. (formerly Nuvelo, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2009
Business Overview: ARCA is a development-stage biopharmaceutical company focused on genetically-targeted therapies for heart failure. Its lead candidate, Gencaro, is under FDA review with a PDUFA decision date of May 31, 2009. The company has no product revenue to date.
Material Event: On January 27, 2009, the company completed a reverse merger with Nuvelo, Inc. ARCA Colorado is the accounting acquirer. The transaction resulted in a significant increase in cash resources and the assumption of Nuvelo's liabilities and assets.
Key Financial Metrics
| Metric (in thousands) | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income (Loss) | $9,933 | $(3,876) |
| Net Income Attributable to Common Stockholders | $9,017 | $(3,890) |
| Loss from Operations | $(15,386) | $(3,995) |
| Cash and Cash Equivalents (Ending) | $25,920 | $11,738 |
| Marketable Securities (Ending) | $9,368 | $0 |
| Total Current Assets | $36,944 | $9,678 |
| Total Current Liabilities | $14,766 | $15,830 |
| Bank Note Payable (Outstanding) | $3,472 | $3,948 |
Note: Q1 2009 Net Income is driven by a non-cash "Gain on Bargain Purchase" of $25.282 million resulting from the merger. Operating cash flow remains negative.
Material Changes vs. Prior Period
- Merger Impact: The reverse merger with Nuvelo, Inc. fundamentally altered the balance sheet. Cash and cash equivalents increased by $18.18 million, primarily due to $30.4 million in cash acquired from Nuvelo.
- Operating Expenses: Total costs and expenses increased from $3.995 million in Q1 2008 to $15.386 million in Q1 2009. This includes $5.47 million in merger transaction costs and increased R&D/SG&A due to integration activities and preparation for potential commercialization.
- Equity Structure: All outstanding Series A and Series B preferred stock was converted to common stock in connection with the merger. Common shares outstanding increased from 954,420 (Dec 31, 2008) to 7,569,903 (Mar 31, 2009).
- Liabilities: The company assumed significant facility exit costs ($12.24 million total liability) related to Nuvelo's Sunnyvale facility lease.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items
- Gain on Bargain Purchase: A one-time gain of $25.282 million was recorded due to the fair value of net assets acquired exceeding the acquisition consideration. This is the primary driver of the reported net income for the quarter.
- Merger Transaction Costs: $5.47 million in costs were expensed in Q1 2009 related to the merger.
Outlook and Guidance
- Going Concern: Management states there is "substantial doubt" about the company's ability to continue as a going concern beyond December 31, 2009, unless it secures additional capital or completes a strategic transaction.
- Strategic Alternatives: Due to capital market disruptions, the company is exploring strategic alternatives for commercializing Gencaro (e.g., licensing or combination) rather than building an internal sales force immediately.
- Capital Needs: If Gencaro is approved, an $8 million milestone payment to CPEC is due within six months. The company expects to fund operations through at least December 31, 2009, pending restructuring.
Risks
- Regulatory Approval: The FDA review of the Gencaro NDA may be extended beyond the May 31, 2009 PDUFA date. Failure to obtain approval would prevent commercialization.
- Liquidity: The company has no revenue and relies on financing. Failure to raise capital or complete a strategic deal could force liquidation.
- Legal Proceedings: The company is defending against securities class action lawsuits related to Nuvelo's former product (alfimeprase) and Variagenics' IPO. Management believes insurance will cover costs, but outcomes are uncertain.
Investor Verification Checklist
- FDA Decision Date: Verify the status of the Gencaro NDA review and whether the May 31, 2009 PDUFA date has been extended.
- Cash Runway: Confirm current cash burn rate and whether the company has secured additional financing or a strategic partner to extend operations beyond December 2009.
- Milestone Obligations: Review the terms of the CPEC license agreement regarding the $8 million payment due upon FDA approval.
- Facility Exit Costs: Monitor the resolution of the assumed Sunnyvale facility lease liability ($12.24 million) and potential sublease income.
- Legal Status: Track the progress of the securities class action lawsuits regarding Nuvelo and Variagenics to assess potential uninsured liabilities.